GE HealthCare Technologies Inc. GEHC NDXSPX
Company Overview
GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Advanced Visualization Solutions (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, X-ray systems, and women's health products. The AVS segment provides ultrasound, image guided therapies, and interventional solutions for screening, diagnosis, treatment, and monitoring of certain diseases in clinical areas, such as women's health, cardiovascular, and comprehensive care ultrasound as well as surgical visualization and guidance products. The PCS segment provides medical devices, consumables, services, and digital solutions. Its portfolio includes patient monitoring, diagnostic cardiology, consumables and services, digital solutions, maternal infant care, and anesthesia products. The PDx segment supplies diagnostic agents, including CT, angiography and X-ray, MR, single-photon emission computed tomography, and positron emission tomography to the radiology and nuclear medicine industries. The segment also provides contrast media pharmaceuticals that are administered to a patient prior to certain diagnostic scans to increase the visibility of tissues or structures during imaging exams; and molecular imaging agents or radiopharmaceuticals, which are molecular tracers labeled with radioisotopes. The company has a strategic collaboration with DeepHealth. GE HealthCare Technologies Inc. was formerly known as GE Healthcare Holding LLC and changed its name to GE HealthCare Technologies Inc. in December 2022. The company was incorporated in 2022 and is headquartered in Chicago, Illinois.
Why Investors Should Care
Generates a return on equity of 19.5%, reflecting efficient use of shareholder capital.
Trades at a P/E of 14.8, below the sector median of 25.4.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $20.62B (+4.8% YoY); net profit $2.08B.
- Trailing 12 Months Year-on-year growth — revenue +7.4%, earnings -30.9%.
- 5-Year Trend Long-term compounding — revenue CAGR 4.1%, profit CAGR -1.9%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 4.07% |
| 1 Year: | 7.40% |
Compounded Profit Growth
| 5 Years: | -1.87% |
| 1 Year: | -30.90% |
Stock Price Performance
| 1 Year: | -17.03% |
| 6 Months: | -29.32% |
| 3 Months: | -16.48% |
| 1 Month: | -4.42% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)39.39 · Neutral
P/E of 14.79 is below the sector median of 25.41 — relatively cheaper than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Generates positive free cash flow.
CONS
- Earnings shrank at -1.9% CAGR over 5 years.
- Trading 30.0% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | GEHC GE HealthCare Technologies Inc. NDXSPX | 61.66 | 14.79 | $28.05B | 0.21% | 9.94% | 19.46% | 4.07% | -1.87% |
| 2 | LLY Eli Lilly and Company SPX | 1,152.54 | 41.02 | $1.03T | 0.61% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 253.85 | 29.45 | $611.07B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.78 | 119.40 | $432.48B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 425.19 | 32.02 | $386.13B | 2.27% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 120.78 | 34.02 | $298.31B | 2.86% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 164.50 | 24.81 | $255.12B | 1.77% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 534.07 | 29.33 | $198.47B | 0.40% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 355.25 | 24.69 | $191.73B | 2.84% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.34B | 4.48B | 4.58B | 4.71B | 4.82B | 4.82B | 4.65B | 4.84B | 4.86B | 4.78B | 5.01B | 5.14B | 5.13B |
| Gross Profit | 1.68B | 1.80B | 1.77B | 1.89B | 1.94B | 1.94B | 1.90B | 2.00B | 2.03B | 2.01B | 1.99B | 1.99B | 1.98B |
| Operating Income | 509.00M | 631.00M | 605.00M | 559.00M | 570.00M | 617.00M | 540.00M | 608.00M | 676.00M | 629.00M | 654.00M | 653.00M | 515.00M |
| Net Income | 389.00M | 485.00M | 487.00M | 372.00M | 418.00M | 375.00M | 374.00M | 428.00M | 470.00M | 564.00M | 486.00M | 446.00M | 389.00M |
| Diluted EPS | 0.86 | 1.07 | 1.07 | 0.41 | 0.91 | 0.82 | 0.81 | 0.93 | 1.02 | 1.23 | 1.06 | 0.98 | 0.85 |
| R&D Expense | 238.00M | 257.00M | 260.00M | 270.00M | 298.00M | 322.00M | 324.00M | 327.00M | 316.00M | 344.00M | 302.00M | 292.00M | 345.00M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 17.59B | 18.34B | 19.55B | 19.67B | 20.62B |
| Gross Profit | 7.17B | 7.18B | 7.92B | 8.21B | 8.25B |
| Operating Income | 2.79B | 2.52B | 2.44B | 2.62B | 2.76B |
| Net Income | 2.25B | 1.92B | 1.57B | 1.99B | 2.08B |
| Diluted EPS | 4.95 | 4.22 | 3.03 | 4.34 | 4.55 |
| R&D Expense | 816.00M | 1.03B | 1.21B | 1.31B | 1.26B |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Total Assets | - | - | 27.54B | 32.45B | 33.09B | 36.91B |
| Total Equity | 14.75B | 16.68B | 9.36B | 7.13B | 8.45B | 10.38B |
| Cash & Equivalents | - | - | 1.44B | 2.49B | 2.87B | 4.49B |
| Long Term Debt | - | - | 8.23B | 8.44B | 7.45B | 9.49B |
| Total Liabilities | - | - | 17.95B | 25.14B | 24.44B | 26.31B |
| Current Liabilities | - | - | 7.19B | 8.98B | 9.55B | 9.11B |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Investing Cash Flow | -1.76B | -398.00M | -558.00M | -914.00M | -1.05B |
| Financing Cash Flow | -263.00M | -822.00M | -478.00M | -573.00M | 617.00M |
| Share Buybacks | - | - | 0 | 0 | 200.00M |
| Dividends Paid | 0 | 0 | 41.00M | 55.00M | 64.00M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | 40.8% | 39.1% | 40.5% | 41.7% | 40.0% |
| Operating Margin % | 15.9% | 13.8% | 12.5% | 13.3% | 13.4% |
| Net Margin % | 12.8% | 10.4% | 8.0% | 10.1% | 10.1% |
| ROE % | 13.5% | 20.5% | 22.0% | 23.6% | 20.1% |
| ROCE % | - | 12.4% | 10.4% | 11.2% | 9.9% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 7.91% | 35.98M | $2.31B |
| 2 | Dodge & Cox Inc. | 6.88% | 31.31M | $2.01B |
| 3 | Vanguard Capital Management LLC | 6.35% | 28.86M | $1.86B |
| 4 | Capital Research Global Investors | 4.64% | 21.11M | $1.36B |
| 5 | State Street Corporation | 4.52% | 20.54M | $1.32B |
| 6 | Vanguard Portfolio Management LLC | 4.22% | 19.18M | $1.23B |
| 7 | Harris Associates L.P. | 3.43% | 15.59M | $1.00B |
| 8 | Geode Capital Management, LLC | 2.73% | 12.40M | $797.48M |
| 9 | Barrow, Hanley Mewhinney & Strauss, LLC | 2.61% | 11.88M | $764.36M |
| 10 | Hotchkis & Wiley Capital Management, LLC | 2.19% | 9.97M | $641.08M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for GEHC
symbol__ Stock Quote Price and Forecast - CNN
<a href="https://news.google.com/rss/articles/CBMiUEFVX3lxTE5adHdmVDFNQnFOZU5vQUVzVjhWSjJJTV9GUmlQbjg1ek1qRmQ3dW5BaHhid0htMHhVT09Sd0hVbl9UN2E2UjhTQnpiYVduM2dM?oc=5" target="_blank">symbol__ Stock Quote Price and Forecast</a> <fon…
Why GE HealthCare Technologies (GEHC) Stock Is Down Today - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxQdEN6X25WajBEcEQwNl9tWlVsSm00TWhSTUlEd0s1OC1SMHJSS0pvWEN0VGhlUmNod1FYZmdHdElXWU9XVHQ5OVhjb2Y0eDExNFpLZl8xVVR3MEVCR19FQk9Lcy1JLTdlQ2hZdU8tV1ZScFE3YkRRWDJPQW5lb3VabWZWVG5aQkZFWnZtb3…
GE HealthCare Technologies Inc. stock falls Tuesday, underperforms market - MarketWatch
<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxPcEg0NWdySWxqWFAxLVhyaU54eEFfbG5JZVlkTkh4Mlg2YlQ3VjJKaW56dGUyMnFsVHlYaUJWcEc5X0V0aERZTk5ZODZxZjhxVG1jbXJMUHNGdUYyN3ZmNXJsbG9sdW04bXY1czJEYkk1bHVsZFJ0QlI1TFRQS21ONkZTVUZQYWFRekw3VG…
Do Options Traders Know Something About GE HealthCare Stock We Don't? - TradingView
<a href="https://news.google.com/rss/articles/CBMiwgFBVV95cUxQc3JKYWJ5OXBNdll4SU8xRGlEZFU5bzR6ZmZRWmxIMXU2X0R1anVzZVZLRlluckdfa0t0UGdwVnFYdFgzeU1VcG1kZDRMZUtYM2wtYWR0ejk4TDdNeXN2T0tCcC1fV3J6Y0lHamdzajVUS3Y4UmJmeWdxcTBySTJNSFJxSHdBbTk2MVdwVn…
What's going on in today's session: S&P500 gap up and gap down stocks - ChartMill
<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxOcXFXT1UwN3hhVnpUc214c0ZIVW0xcDU3Tk1tS2UyRVBxSnJQOTFrWTdwaU90TnN4WF8xT2VrQ21ybURGLUE3dEVrTHFiZnNWbUFyUk9LMk9xSm5tdjNJVjN6SXpmNWtoeW1qTHZHblJvS2J2eXdpcXQ5aVFsRTY3NGNMXzJkUnpLZzhaLX…
Why GE HealthCare (GEHC) Stock Is Up Today - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxQX2hVNVdJSUhGX1Npakh5NUF2d0dZV1BjeF9BYWJOSEN3VXpaVXFfcjQwdWxXYkppdTRYTHBoT2pxcXhDcF9JQmxILXVnc3l6Zjd2Z3FkREdZaFJ3MVJNT3dUZE5KM0w2UVl6S3lMbDRkX3pDLWJWV2w4UnNVeGtwX3RCcHJlN0pmNGF1ek…
GEHC — Frequently Asked Questions
What is the current share price of GE HealthCare Technologies Inc. (GEHC)?
As of 2026-07-14 21:23 PDT, GE HealthCare Technologies Inc. (GEHC) trades at $61.66 on NasdaqGS. Its 52-week range is $59.48 to $88.08.
What is the market capitalisation of GEHC?
GE HealthCare Technologies Inc. (GEHC) has a market capitalisation of $28.05B on NasdaqGS.
What is the P/E ratio of GEHC?
GEHC trades at a trailing price-to-earnings (P/E) ratio of 14.79. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 2.78.
Does GEHC pay a dividend?
GE HealthCare Technologies Inc. (GEHC) currently offers a dividend yield of 0.21%.
What is the return on equity (ROE) of GEHC?
GEHC has a return on equity (ROE) of 19.46%. Its return on capital employed (ROCE) is 9.94%.
Is GEHC a good stock to buy?
This page provides a data-driven analysis of GE HealthCare Technologies Inc. (GEHC), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.